Clinical trial
PXD101 in Treating Patients With Acute Myeloid Leukemia
NCT00357032 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00357032 |
|---|---|
| Title | PXD101 in Treating Patients With Acute Myeloid Leukemia |
| Official title | A Phase 2 Study of PXD101 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or Patients Over 60 With Newly-Diagnosed Acute Myelogenous Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8 and 3 more |
| Intervention type | Drug, Other |
| Interventions | belinostat, laboratory biomarker analysis |
| Enrollment | 12 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2010 |
| First posted | Jul 27, 2006 |
| Last update posted | Apr 17, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: